

Real-world monitoring of BNT162b2 vaccine-induced SARS-CoV-2 B and T cell immunity in naive healthcare workers: a prospective single center study

1 Bas Calcoen¹, Kim Callebaut², Aline Vandebulcke¹, Nico Callewaert², Xavier Bossuyt³,
2 Johan Van Weyenbergh⁴, Piet Maes⁴, Maya Imbrechts⁵, Thomas Verduyck⁶, Hendrik Jan
3 Thibaut⁶, Dorinja Zapf⁷, Kersten Dieckmann⁷, Karen Vanhoorelbeke^{1,5}, Nick Geukens⁵,
4 Simon De Meyer¹, Wim Maes^{5*}

5

6 ¹Laboratory for Thrombosis Research, KU Leuven campus Kulak Kortrijk, Kortrijk, Belgium

7 ²AZ Groeninge Hospital, Department of Laboratory Medicine, Kortrijk, Belgium

8 ³Department of Microbiology, Immunology and Transplantation, KU Leuven and Department of
9 Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium

10 ⁴Laboratory for Clinical and Epidemiological Virology, KU Leuven Rega Institute, Leuven,
11 Belgium

12 ⁵PharmAbs, The KU Leuven Antibody Center, KU Leuven, Leuven, Belgium,

13 ⁶Laboratory of Virology and Chemotherapy KU Leuven Rega Institute, Leuven, Belgium

14 ⁷Institut für experimentelle Immunologie, EUROIMMUN Medizinische Labordiagnostika AG ,
15 Lübeck, Germany

16

17 *** Correspondence:**

18 Wim Maes

19 wim.maes@kuleuven.be

20 **Keywords: SARS-CoV-2, BNT162b2 vaccine, real-world monitoring, B and T cell response,**
21 **breakthrough infection, naive healthcare workers.**

healthcare workers

22 **Abstract**

23 **Background:** Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the
24 ongoing COVID-19 pandemic. To prevent the massive COVID-19 burden, several vaccination
25 campaigns were initiated. We performed a single center observational trial to evaluate adaptive
26 immunity in naive healthcare workers upon BNT162b2 vaccination.

27 **Methods:** Serological analysis was performed through conventional immunoassays. Antibody
28 functionality was analyzed via in vitro neutralization assays. Circulating receptor-binding domain
29 (RBD) specific B cells were assessed via flowcytometry. The induction of SARS-CoV-2 specific
30 T cells was investigated through interferon- γ release assay combined with flowcytometric profiling
31 of activated CD4 and CD8 T cells.

32 **Results:** Three months after vaccination, all but one of the subjects (N = 31) displayed vaccine-
33 induced neutralizing antibodies. In 10 out of 31 subjects, circulating RBD specific B cells were
34 found of which the rate showed moderate correlation to serological parameters. Specific interferon-
35 γ release was present in all subjects and correlated with the significant upregulation of CD69 on
36 CD4+ and CD8+ T cells and CD40L on CD4+ T cells. Interestingly, no relation was found between
37 B and T cell parameters. In addition, one symptomatic breakthrough infection with the SARS-
38 CoV-2 alpha variant of concern was reported.

39 **Conclusion:** Three months post vaccination, both humoral and cellular immune responses are
40 detectable in all but one participant. No correlation was found between the magnitude of both B
41 and T cell responses.

healthcare workers

42 **1 Introduction**

43 Back in December 2019, multiple cases with serious pneumonia of unknown origin (later renamed
44 as coronavirus disease 19 or COVID-19) were described in Wuhan, China (1). Not long afterwards,
45 the causative pathogen was identified via real-time polymerase chain reaction (RT-PCR) as a novel
46 sarbecovirus (sub-genus of the β -coronaviridae) and named severe acute respiratory syndrome
47 coronavirus 2 (SARS-CoV-2) (2,3).

48 Within a few weeks, SARS-CoV-2 rapidly spread internationally and on 30 January 2020, the
49 world health organization (WHO) declared the outbreak a public health emergency of international
50 concern (4). As a result, many countries introduced strict socio-economic rules (e.g. lockdown,
51 mouth mask) to limit viral spreading and prevent a total collapse of their healthcare system (5).

52 During the pandemic, multiple strategies including the development of a SARS-CoV-2 vaccine
53 were urgently initiated to lower the massive SARS-CoV-2 related burden. Multiple vaccine
54 development strategies were explored, including nucleic acid-based (e.g. BNT162b2 or
55 Comirnaty[®] (6,7), mRNA-1732 or Spikevax[®] (8,9)), adenovector-based (e.g. Vaxzevria[®] (10),
56 COVID19 vaccine Janssen[®] (11,12)) and protein-based (Sanofi-GSK[®] (13)) vaccines of which
57 several products received conditional authorization by either the European Medical Agency (EMA)
58 or Food and Drug Administration (FDA) at the end of 2020. This resulted in the roll-out of
59 international vaccination campaigns at an unprecedented scale and speed.

60 However, due to the emergence of several SARS-CoV-2 variants of concern (VoC) that already
61 led to new infection waves around the globe (14,15), there is reasonable concern whether the
62 immune response evoked by the currently available vaccines is sufficient to cover these VoC. For
63 example, it is known that several of these SARS-CoV-2 VoC have mutations within their spike (S)
64 protein or receptor-binding domain (RBD) region and therefore could be able to escape
65 functionally active vaccine-induced antibodies that only bind to unique epitopes present on Wuhan
66 strain S or RBD (16). In addition, only a limited number of studies reveal mid-term (i.e. longer
67 than 2 months post mRNA vaccination) sustainability data of vaccine-induced de novo responses
68 to SARS-CoV-2 within healthy subjects (17,18). Finally, most vaccine monitoring studies are often
69 solely based on the evaluation of serological responses (19), although it is known from for example
70 vaccination against smallpox that specific T cells can be detected up to 75 years after vaccination
71 and thus are crucial for long-term immunity (20,21). Indeed, few groups have looked at both
72 vaccine-induced B and T cell immunity, in particular in healthy SARS-CoV-2-naive volunteers
73 (22,23) as most trials focused on either immunocompromised or SARS-CoV-2 convalescent
74 patients. Concerning specific T cell responses upon mRNA-based SARS-CoV-2 vaccination,
75 available data are limited to phase I/II studies (24) of the Comirnaty[®] vaccine and studies that either
76 assessed short-term T cell response (i.e. up to one month after booster vaccination) (25,26) or
77 focused on T cell responses upon prime or boost vaccination (27,28). Of note, there are several,
78 sometimes contradictory reports concerning both the occurrence rate (29,30) and severity (31,32)
79 of post mRNA vaccination breakthrough infections (BTI).

80 To address these gaps, we monitored vaccine elicited B and T cell responses in a real-world setting.
81 Hereto, SARS-CoV-2 naive healthcare workers were followed for three months after vaccination
82 with the BNT162b2 SARS-CoV-2 vaccine (Comirnaty[®]) in a prospective single center study.

healthcare workers

83 **2 Materials and Methods**

84 **2.1 Study design**


85 **2.1.1 Recruitment**

86 During January 2021, professional healthcare workers from the supraregional AZ Groeninge
 87 hospital (Kortrijk, Belgium) qualified to receive the BNT162b2 (Comirnaty®) vaccine were
 88 contacted via the hospital’s newsletter for voluntary enrollment in this study. Healthcare workers
 89 were included after signing an informed consent form. Participants were excluded if they met at
 90 least one of the following criteria: severe acute infection of any kind, pregnancy, primary
 91 immunodeficiency (PID), chronic treatment with immunomodulatory agents (e.g. anti-TNF-α
 92 agents, corticosteroids), documented earlier natural infection with SARS-CoV-2 or positive
 93 serology (including either anti-S IgG, anti-S IgA or anti-nucleocapsid (N) IgG) found at baseline
 94 sampling.

95 **2.1.2 Sampling**

96 A baseline sampling moment prior to vaccination was performed either one day before or on the
 97 day of prime vaccination (t_{pre}). Comirnaty® administration was performed as indicated by the
 98 manufacturer and upon the recommendation by the Belgian Superior Health Council. A second
 99 sampling was performed three months after t_{pre} (t_{3m}). In case a participant, after receiving two
 100 vaccines, presented with COVID-19 symptoms (e.g. dry cough, fever and/or headache) and was
 101 positive for SARS-CoV-2 via real-time polymerase chain reaction (RT-PCR), he/she was
 102 considered to experience a symptomatic BTI. In this situation, additional sampling was scheduled
 103 as soon as possible (t_{BTI}). Sampling details are visualized in **Figure 1**.

104



105

106 **Figure 1. Study design and timeline.** A total of 32 healthcare workers were enrolled. One day
 107 before or on the day of the first BNT162b2 vaccine, a first baseline sampling moment was
 108 scheduled (t_{pre}). A second sampling moment (t_{3m}) was planned between 80-100 days after baseline.

healthcare workers

109 On each moment, serum was collected to determine SARS-CoV-2 serology and neutralization
110 efficacy whereas blood was used both for isolating PBMCs to detect circulating RBD specific B
111 cells and to assess both SARS-CoV-2 specific T cell activity and IFN- γ release. When a participant
112 developed symptoms and was tested positive via RT-PCR after receiving two vaccines, an
113 additional sampling moment was planned (t_{BTI}). At t_{BTI} , a nasopharyngeal swab was collected to
114 execute viral whole genome sequencing. Also, a VSV pseudovirus neutralization assay was
115 additionally performed at this timepoint. Abbreviations: PBMC = peripheral blood mononuclear
116 cells, IFN- γ = interferon γ , RT-PCR = real-time polymerase chain reaction, VSV = vesicular
117 stomatitis virus, VoC = variants of concern. This figure was created using Biorender
118 (www.biorender.com).

119

120 2.1.3 Serum and peripheral blood mononuclear cell (PBMC) isolation

121 Venous blood from three K₂-EDTA tubes was used to isolate PBMCs via density gradient isolation
122 with Ficoll (lymphoprepTM, STEMCELL technologies, Norway) using SepMate tubes
123 (STEMCELL technologies, Norway). PBMCs were diluted in 90 % fetal calf serum containing 10
124 % DMSO, divided in aliquots and stored in liquid nitrogen after a controlled cooling procedure.
125 When needed, PBMC aliquots were shortly thawed at 37 °C and washed two times in dPBS
126 (GibcoTM Life Sciences, Thermo Fisher Scientific, USA) with a centrifugation step at 300 g for 7
127 min at 4 °C after each washing. Serum was collected from the SSTTM II Advance tubes and stored
128 at -20 °C.

129 2.1.4 Ethical approval

130 This clinical trial was registered at the EU Clinical Trial Register with ID 2021-001304-15. This
131 trial was performed according to the declaration of Helsinki and was approved by both the local
132 Ethical Committee of the AZ Groeninge hospital (B3962021000022) and the Belgium Federal
133 Agency of Drugs and Health Products (FAGG; protocol no. AZGS2021005).

134 2.2 Serological parameters

135 2.2.1 Anti-S IgA and IgG assay

136 Serum anti-S IgA antibodies were measured with the Anti-SARS-CoV-2 IgA enzyme
137 immunoassay from EUROIMMUN (Lübeck, Germany) on an ETI-Max 3000 instrument from
138 DiaSorin (Saluggia, Italy). Following the instructions from the manufacturer, samples with a cut-
139 off index greater or equal to 1.1 were labeled as positive. Serum anti-S IgG titers were measured
140 with the VIDAS SARS-COV-2 IgG (9COG) enzyme immunoassay from Biomérieux (Marcy-
141 l'Etoile, France) on a VIDAS 3 instrument from the same manufacturer. According to the
142 manufacturer's instructions, samples with a cut-off index greater or equal to 1.0 were considered
143 positive.

144 2.2.2 Anti-RBD IgG assay

145 Enzyme-linked immunosorbent assay (ELISA) plates (Corning Costar; cat. Nr. 3590) were coated
146 overnight with His₆-tagged RBD. Plates were blocked for 2 h at room temperature (RT) using
147 blocking buffer (PBS + 1 % BSA) and washed (wash buffer PBS + 0.002 % Tween 80) six times.
148 Monoclonal anti-RBD calibrator antibody (Sino Biologicals; cat. Nr. 40150-D004) and serum

healthcare workers

149 samples (diluted minimum 500-fold) were incubated for 2 h at RT (buffer PBS + 0.1 % BSA +
150 0.002 % Tween 80). After an additional washing step, goat antihuman (GAH) IgG conjugated with
151 horseradish peroxidase (HRP) was added (1:5000 dilution) and incubated for 1 h at RT.
152 Subsequently, washing was performed and the plate was developed using o-phenylenediamine
153 dihydrochloride (OPD; 0.4 g/L) and H₂O₂ (0.003 %) in citrate buffer. After 30 min, the reaction
154 was stopped with H₂SO₄ (4 M). The absorbance was measured at 492 nm and the dose-response
155 curve was analyzed by non-linear regression using GraphPad Prism 9.0.0 (Graph Software, San
156 Diego, CA, USA). The assay was validated by measuring assay cut-off values for detection and
157 quantification, accuracy, imprecision and dilutional linearity (33). Sample concentrations were
158 determined using the anti-RBD calibrator antibody and WHO International Standard Serum
159 (NIBSC ref 20-136) (34).

160 2.2.3 Anti-N IgG assay

161 The presence of serum anti-N IgG antibodies was determined via the Anti-SARS-CoV-2-NCP
162 (IgG) enzyme immunoassay from EUROIMMUN on an ETI-Max 3000 instrument from DiaSorin.
163 Samples that had a cut-of index greater or equal to 1.1 were considered positive as recommended
164 by the instructions from the manufacturer.

165 2.3 Antibody functionality: neutralization assay

166 2.3.1 In vitro neutralization assay

167 Determination of the neutralizing capacity of the vaccine-induced antibodies was generated using
168 the EUROIMMUN SARS-CoV-2 NeutraLISA assay according to the manufacturer's instructions.
169 Samples were diluted 1:5 in sample buffer. A photometric measurement was made on a wavelength
170 of 450 nm together with a reference wavelength of 620 nm. Semiquantitative results were generated
171 by calculating a ratio of the extinction values of the sample over the mean extinction value of the
172 blank (measured in duplicate) and were presented as percentage inhibition. Percentage inhibition
173 values lower than 20 were defined as negative, between 20 and 35 as borderline and higher or equal
174 to 35 as positive. Lot-specific control concentrates (positive and negative) were used as assay
175 references.

176 2.3.2 Vesicular stomatitis virus (VSV) pseudovirus neutralization assay

177 VSV S-pseudotypes were generated as described previously (35). Briefly, HEK-293T cells
178 (SARS-CoV-2) were transfected with the respective S protein expression plasmids, and one day
179 later infected (MOI = 2) with green fluorescent protein (GFP)-encoding VSVΔG backbone virus
180 (purchased from Kerafast). Two hours later, the medium was replaced by medium containing anti-
181 VSV-G antibody (I1-hybridoma, ATCC CRL-2700) to neutralize residual VSV-G input. After 24
182 h incubation at 32 °C, the supernatants were harvested. To quantify neutralizing antibodies
183 (nAbs), serial dilutions of serum samples were incubated for 1 h at 37 °C with an equal volume
184 of S pseudotyped VSV particles and inoculated on Vero E6 cells (SARS-CoV-2) for 18 h.

185 The percentage of GFP expressing cells was quantified on a Cell Insight CX5/7 High Content
186 Screening platform (Thermo Fischer Scientific) with Thermo Fisher Scientific HCS Studio
187 (v.6.6.0) software. Neutralization IC₅₀ values were determined by normalizing the serum
188 neutralization dilution curve to a virus (100%) and cell control (0%) and fitting in GraphPad Prism

healthcare workers

189 (inhibitor vs. response, variable slope, four parameters model with top and bottom constraints of
190 100 % and 0 % respectively).

191 2.4 Stimulation of SARS-CoV-2 specific T cells

192 Heparinized whole blood was used for the EUROIMMUN SARS-CoV-2 interferon gamma release
193 assay (IGRA) kit that was executed according to the manufacturer's instructions adapted as
194 described below ([Supplementary Figure 1](#)). Heparinized whole blood was transferred into three
195 different tubes (BLANK, COV2 and STIM) followed by an incubation step for 20-24 h at 37 (\pm 1)
196 °C after inverting 6 times. Following incubation, the tubes were centrifuged at RT for 10 min at
197 700 g. Approximately 200 μ L of stimulated heparinized plasma from each tube was pipetted into
198 Eppendorf tubes and centrifuged again at RT for 10 min at 12,000 g. Finally, the supernatant was
199 pipetted into cryovials and stored at -20 °C until measurement via the EUROIMMUN Quant-T-
200 Cell ELISA (interferon- γ (IFN- γ) ELISA). Importantly, the pellet containing the cellular fraction
201 was used for additional flowcytometry (see 2.5.2 T cell phenotyping and activity).

202 2.4.1 Interferon γ (IFN- γ) ELISA

203 Specific SARS-CoV-2 induced IFN- γ release was determined via the EUROIMMUN Quant-T-
204 Cell ELISA according to the manufacturer's instructions. A photometric measurement was
205 performed at a wavelength of 450 nm with a reference measurement at 620 nm. For each tube,
206 IFN- γ concentrations were determined using a standard curve that was fitted via GraphPad Prism
207 (four parameters model without restrictions). Then, for each subject, the determined IFN- γ
208 concentration from the unstimulated control (BLANK) was subtracted from the determined IFN- γ
209 concentrations of both the stimulation control (STIM) and SARS-CoV-2 stimulated condition
210 (COV2). Lot-specific lyophilized calibrators and controls were used as a standard.

211 2.5 Flowcytometric analyses

212 2.5.1 Circulating RBD specific B cells

213 Thawed PBMCs were stained with a selective B cell staining panel that is listed in [Supplementary](#)
214 [Table 1](#). After a final washing step, the pellets were resuspended in 300 μ L dPBS and immediately
215 acquired on the flowcytometer (FACSVerser device, BD Biosciences, USA).

216 Living B cells were selected from the PBMC pool via a CD3⁻/CD19⁺/Zombie⁻ gating strategy
217 ([Supplementary Figure 2A](#)). Specific B cell reactivity against SARS-CoV-2 was assessed with
218 wild type RBD-biotin and PE-streptavidin. Within each sample, a negative control tube (without
219 RBD-biotin) was included to correct for sample-specific background. For each staining
220 experiment, a sample with documented RBD specific B cells was used as a positive control for
221 quality assessment.

222 2.5.2 T cell phenotyping and activity

223 The remaining cell pellet from the IGRA tubes (see 2.4 Stimulation of SARS-CoV-2 specific T
224 cells) was immediately resuspended with dPBS in a total volume of 500 μ L. A whole blood staining
225 was performed on the reconstituted samples. In summary, T cell staining ([Supplementary Table](#)
226 [1](#)) was performed in 150 μ L of the reconstituted samples. Following incubation for 30 min at 4 °C,
227 3 mL of red blood cell (RBC) lysis buffer (BD FACSTM lysing solution, BD Biosciences, USA)
228 was added for 5 min at RT to allow RBC lysis. After extensive washing, the pellets were

healthcare workers

229 resuspended in 350 μ L dPBS and immediately acquired on the flowcytometer. T cells were selected
230 via gating (**Supplementary Figure 2B**) on the CD3⁺ population and further divided into helper T
231 cells (T_H; CD4⁺/CD8⁻), circulating follicular helper T cells (T_{CFH}; CD4⁺/CD8⁻/CXCLR5^{hi}) and
232 cytotoxic T cells (T_C; CD4⁻/CD8⁺). Membrane markers used to assess T cell activation were CD40L
233 and CD69. The gating strategy was based on the fluorescence minus one (FMO) signal retrieved
234 for each individual fluorochrome. For each subject, besides the condition with SARS-CoV-2
235 specific antigens, an unstimulated negative (BLANK) and a positive control (STIM) condition
236 were available to respectively correct for background and to assess intrinsic cell functionality.

237 **2.6 Viral whole genome sequencing**

238 RNA extraction was performed by using the DEXR-15-LM96 kit for automated extraction
239 (Diagenode, Seraing, Belgium) with 350 μ L sample input. Extracted RNA was eluted from
240 magnetic beads in 50 μ L of UltraPure DNase/RNasefree distilled water. Following RNA extraction,
241 cDNA was synthesized followed by multiplex PCR amplification using a modified version of the
242 ARTIC V3 LoCost protocol with the Midnight primer set (1200 bp amplicons). The libraries were
243 sequenced on a MinION using R9.4.1 flow-cells (Oxford Nanopore Technologies, Oxford, UK)
244 and MinKnow software v21.02.1. The resulting fast5 reads were basecalled and demultiplexed
245 using Guppy v5.0.16 in super accuracy mode. Genome assembly was performed using the ARTIC
246 bioinformatics pipeline v1.1.3, which entails adapter trimming, mapping to the reference strain
247 Wuhan-Hu-1 (MN908947), as previously described (36).

248 **2.7 Statistical analyses**

249 Statistical analysis was performed using both Microsoft Excel (version 365 for Windows,
250 Microsoft Corporation, USA) and GraphPad Prism (version 9.0.0 for Windows, GraphPad
251 Software, USA). Flowcytometric data was processed using FCS Express (version 7 research edition
252 for Windows, De Novo Software, USA). Continuous variables were presented as mean \pm standard
253 deviation if the Shapiro-Wilk normality test was successful or as either median \pm interquartile range
254 (IQR) or median with the interval between quartile 1 and 3 (Q1-Q3) if not. Confidence intervals
255 (CI) of medians were calculated via the standard method described by Zar JH (37). Discrete and
256 categorical variables were shown as respectively numbers or categories with percentages between
257 brackets. Comparison between parameters was done using a student t-test or one-way ANOVA
258 with a post-hoc correction for multiple comparisons via Tukey's test and after assessment of
259 constant variance using Levene's test if normality was met or with the respective non-parametric
260 alternatives when not. Paired analyses were done if appropriate. Correlation between parameters
261 was assessed via bivariate analysis expressed via a Pearson determination coefficient (R²); a
262 Pearson r or via a Spearman r if there was no normality and also via a multivariate analysis using
263 principal component analysis (PCA). For all tests, the significance was set at a two-tailed
264 probability level of 0.05.

265 **3 Results**

266 **3.1 Trial characteristics and exclusions**

267 All enrolled healthcare workers (N = 32) were Caucasian and exact half of them were women. The
268 age ranged between 25 and 51 years with a mean of 36 \pm 7 (95% confidence interval (CI): 33-38)
269 years. During this trial, one subject was excluded for all analyses because she dropped out between

healthcare workers


270 t_{pre} and t_{3m} (**Figure 1**). Anti-N IgG titers were measured at both t_{pre} and t_{3m} to exclude (subclinical)
271 natural SARS-CoV-2 infection. For both timepoints, the anti-N IgG titers remained below the index
272 value with a mean of 0.022 ± 0.038 and 0.100 ± 0.113 at respectively t_{pre} and t_{3m} .

273 3.2 Antibody and B cell response three months after BNT162b2 vaccination

274 3.2.1 BNT162b2 vaccination induces functionally active antibodies

275 Three months after BNT162b2 vaccination, the vaccine-induced antibody response was described
276 via both serology and in vitro neutralization assays. Spike-specific antibodies are represented in
277 **Figure 2**.

278



279

280 **Figure 2. SARS-CoV-2 anti-S serology (N = 31).** (A) anti-S IgG titers, (B) anti-S IgA titers and
281 (C) simple linear regression and correlation between anti-S IgG and IgA antibodies 3 months after
282 BNT162b2 vaccination. Error bars represent median with IQR. Abbreviations: S = spike, pre =
283 baseline sampling moment before vaccination, 3m = 3 months after baseline, IQR = interquartile
284 range.


285

286 At baseline, all 31 subjects were negative for both anti-S IgG and IgA with a median index titer of
287 0.010 ± 0.020 (95% CI: 0.000-0.020) and 0.371 ± 0.194 (95% CI: 0.320-0.474) respectively. Three
288 months after vaccination, all individuals showed detectable anti-S IgG antibodies with a median
289 index titer of 26.8 ± 9.23 (95% CI: 24.7-31.1) of which two of these individuals had no anti-S IgA
290 response (**Figure 2A-B**). Anti-S IgG and IgA titers were moderately but significantly correlated
291 with a Spearman r of 0.5798 ($p < 0.001$) and a Pearson R^2 of 0.2692 (**Figure 2C**).

292 Next, anti-RBD IgG titers were determined (**Figure 3A**). In line with the above findings, no anti-
293 RBD IgG antibodies could be detected at baseline (< 160 BAU/mL), whereas all but one had anti-
294 RBD IgG titers three months post-vaccination with a median titer of 827.0 (95% CI: 661.0-1103)
295 with a Q1-Q3 interval of 599.0-1310 BAU/mL.

healthcare workers

296



297

298 **Figure 3. SARS-CoV-2 anti-RBD serology and antibody functionality (N = 31).** (A) anti-RBD
299 IgG titers, (B) in vitro neutralization efficacy and (C) simple linear regression and correlation
300 between anti-RBD IgG and antibody functionality at three months post-BNT162b2 vaccination.
301 Error bars represent median with IQR. Abbreviations: RBD = receptor-binding domain, pre =
302 baseline sampling moment before vaccination, 3m = 3 months after baseline, IQR = interquartile
303 range.

304

305 Additionally, the capacity of the induced antibodies to neutralize the binding between wild type
306 RBD and human ACE2, was assessed. Overall antibody neutralization capacity was high with a
307 median % inhibition compared to a blank control of 93.91 ± 6.08 (95% CI: 90.45-95.13; **Figure**
308 **3B**). A moderate but significant correlation was seen between anti-RBD IgG titers and antibody
309 functionality with a Spearman r of 0.8347 ($p < 0.0001$) and a Pearson R² of 0.3010 (**Figure 3C**).


310 3.2.2 Circulating RBD specific B cells

311 In parallel to the assessment of serology and functionality of the vaccine-induced antibodies, the
312 precursor rate of circulating RBD specific B cells was examined. For each individual, a PBMC
313 aliquot of t_{pre} and t_{3m} were analyzed within the same experiment to allow the detection of vaccine-
314 specific changes. An example of the gating strategy used for the flowcytometric B cell phenotyping
315 is shown in **Supplementary Figure 2A**.

316 The magnitude of CD3⁻/CD19⁺ B cells was comparable between both timepoints and ranged
317 between 1.93 – 14.16 % of gated lymphocytes. Furthermore, a small (0.087 ± 0.068 % of parent,
318 i.e. living B cells) but significant ($p < 0.005$) population of circulating RBD specific B cells was
319 detected in 10 of the 31 individuals (32.26 %) at three months post vaccination (**Figure 4A**). Within
320 these 10 subjects, the rate of circulating RBD specific B cells showed a significant good correlation
321 with anti-RBD IgG titers (Pearson R² = 0.6314, Spearman r = 0.8571 with $p < 0.005$, **Figure 4B**)

healthcare workers

322 and a moderate correlation with antibody functionality (Pearson $R^2 = 0.3398$, Spearman $r = 0.8902$
323 with $p < 0.005$, **Figure 4C**).
324



325 **Figure 4. Flowcytometric determination of both B cell phenotype and rate of circulating RBD**
326 **specific B cells.** (A) Scatter plot representing the circulating RBD specific B cell populations that
327 were found in 10 participants. Each data point represents the percentage of RBD specific B cells
328 after subtraction of the sample-specific background (i.e. condition with RBD-biotin minus
329 condition without RBD-biotin). ** Wilcoxon test: $p < 0.01$. (B) Simple linear regression and
330 correlation between anti-RBD IgG and circulating RBD specific B cells found in 10 participants at
331 three months post-BNT162b2 vaccination. (C) Simple linear regression and correlation between
332 antibody functionality and circulating RBD specific B cells found in 10 participants at three months
333 post-BNT162b2 vaccination. Error bars represent median \pm IQR. Abbreviations: RBD = receptor-
334 binding domain, pre = baseline sampling moment before vaccination, 3m = 3 months after baseline,
335 IQR = interquartile range.
336

337


338 **3.3 T cell immune response three months after BNT162b2 vaccination**

339 **3.3.1 BNT162b2 vaccination induces SARS-CoV-2-specific IFN- γ production by T**
340 **cells**

341 Next, we also defined the SARS-CoV-2 specific T cell response. Firstly, we assessed the vaccine-
342 induced specific IFN- γ release by T cells upon restimulation with SARS-CoV-2 antigens (**Figure**
343 **5**). Three subjects were excluded from these analyses due to technical issues.

344

healthcare workers



345

346 **Figure 5. SARS-CoV-2 specific T cell mediated IFN- γ release (N = 28).** Scatter plot representing
347 the SARS-CoV-2 specific IFN- γ release after subtraction of the unstimulated negative control at
348 both baseline and 3 months after vaccination. The right part of the plot shows the subject-specific
349 fold increase in SARS-CoV-2 specific IFN- γ release. **** Wilcoxon test: $p < 0.0001$. Error bars
350 represent median \pm IQR. Abbreviations: IFN- γ = interferon- γ , pre = baseline sampling moment
351 before vaccination, 3m = 3 months after baseline, IQR = interquartile range.

352

353 The median SARS-CoV-2-specific T cell mediated IFN- γ release post vaccination was $1520 \pm$
354 1287 mIU/mL (95% CI: 836.5-1986) with values ranging between 204.8 and 8523 mIU/mL. These
355 IFN- γ values were significantly higher ($p < 0.0001$) compared to baseline values (median: $34.77 \pm$
356 73.50 mIU/mL). Three months post vaccination, there was at least a three-fold increase of SARS-
357 CoV-2-specific T cell mediated IFN- γ release detected and even exceeding 10,000-fold for some
358 participants. At both timepoints, there was a clear IFN- γ release observed in the stimulation control
359 condition (data not shown).


360 **3.3.2 SARS-CoV-2-specific CD4 and CD8 T cells display an activated phenotype after**
361 **BNT162b2 vaccination**

362 Using the reconstituted cell pellets from the IGRA tubes, we were able to include T cell
363 phenotyping in addition to the SARS-CoV-2 specific IFN- γ release. An example of the applied
364 gating strategy can be retrieved in [Supplementary Figure 2B](#). In accordance with the B cell
365 phenotyping, the magnitudes of CD3⁺ lymphocytes (i.e. T cells), CD4⁺/CD8⁺ cytotoxic T cells (T_C),
366 CD4⁺/CD8⁺ helper T cells (T_H) and CD4⁺/CD8⁻/CXCR5^{hi} circulating follicular T helper cells (T_{CFH})
367 were similar for all three conditions within the IGRA (data not shown).

368 Three months after vaccination, a significant upregulation of the early activation marker CD69 was
369 detected upon SARS-CoV-2 specific restimulation in the T_C ($p < 0.0001$), T_H ($p < 0.0001$) and
370 T_{CFH} ($p < 0.005$) cell subsets ([Figure 6A](#)). Furthermore, CD40L was also significantly upregulated
371 in both T_H ($p < 0.0001$) and T_{CFH} ($p < 0.005$) subsets ([Figure 7A](#)). For each sample, a condition
372 with mitogenic stimulation was analyzed as well as means of quality control (data not shown).

healthcare workers

373




374

375 **Figure 6. Expression of activation marker CD69 on SARS-CoV-2 specific T cells after**
376 **BNT162b2 vaccination (N = 28).** (A) Scatter plot showing the percentages of CD69⁺ T_C, T_H and
377 T_{CFH} cells present in the condition without stimulation (ctrl) and after SARS-CoV-2 specific
378 stimulation (cov2). **** Wilcoxon test: p < 0.0001, *** Wilcoxon test: p < 0.005. (B-C) Simple
379 linear regression and correlation between SARS-CoV-2 specific T cell mediated IFN- γ release and
380 following parameters of cellular immunity: (B) percentage of CD69⁺ T_C cells and (C) percentage
381 of CD69⁺ T_H cells. Error bars represent median \pm IQR. Abbreviations: IFN- γ = interferon- γ , pre =
382 baseline sampling moment before vaccination, 3m = 3 months after baseline, IQR = interquartile
383 range.

384

385 SARS-CoV-2 specific T cell mediated IFN- γ release was moderately but significantly correlated
386 with both CD69⁺ on T_C (Pearson R² = 0.3177, Spearman r = 0.6880 with p < 0.0001; **Figure 6B**)
387 and T_H (Pearson R² = 0.4372, Spearman r = 0.5698 with p < 0.005; **Figure 6C**) and CD40L⁺
388 expression on T_H (Pearson R² = 0.6068, Spearman r = 0.6252 with p < 0.0005; **Figure 7B**).

389



390

391 **Figure 7. Expression of costimulatory molecule CD40L on SARS-CoV-2 specific T cells after**
392 **BNT162b2 vaccination (N = 28).** (A) Scatter plot showing the percentages of CD40L⁺ T_H and

healthcare workers


393 T_{CFH} cells present in the condition without stimulation (ctrl) and after SARS-CoV-2 specific
394 stimulation (cov2). **** Wilcoxon test: $p < 0.0005$, *** Wilcoxon test: $p < 0.005$. (B) Simple
395 linear regression and correlation between SARS-CoV-2 specific T cell mediated IFN- γ release and
396 percentage of $CD40L^+$ T_H cells. Error bars represent median \pm IQR. Abbreviations: IFN- γ =
397 interferon- γ , pre = baseline sampling moment before vaccination, 3m = 3 months after baseline,
398 IQR = interquartile range.

399

400 3.4 The magnitudes of B and T cell response are not correlated three months after 401 BNT162b2 vaccination

402 Finally, we aligned the magnitude of the different SARS-CoV-2 specific B and T cell parameters
403 but no significant linear relations nor correlations could be observed (Pearson $R^2 < 0.15$ and
404 Spearman $r < 0.40$ with $p > 0.10$ in all cases). Also, within the 10 healthcare workers that had
405 circulating RBD specific B cells, the precursor rate was not correlated either with CD69 activated
406 (Spearman $r = 0.0426$, $p > 0.50$) or CD40L activated T cells (Spearman $r = 0.1398$, $p > 0.50$).
407 Additionally, PCA was performed to identify parameters that contribute most to the overall
408 variance found within this cohort (Figure 8).

409



410

411 **Figure 8. Principal component analysis between parameters of both vaccine-induced**
412 **humoral and cellular responses (N = 28).** (A) PC scores plot, (B) loadings plot and (C)
413 proportions of variance graph. Abbreviations: PCA = principal component analysis, PC = principal
414 component.

415

416 First, no clear clustering could be identified from the PC scores plot (Figure 8A). Next, PCA
417 revealed that the loadings of all 11 included variables (circulating RBD specific B cells were
418 excluded) appeared on the same side of the loadings plot, showing that each variable correlated
419 positively with PC 1. Also, two different clusters could be identified based on the loadings plot
420 with PC 2 (Figure 8B). Combining PC 1 and PC 2 explained approximately 60 % of the overall
421 variance in this cohort (Figure 8C).

healthcare workers

422 **3.5 Symptomatic SARS-CoV-2 BTI despite a vaccine-induced functional antibody**
 423 **response and specific T cell immunity**

424 Within the timeframe of this study, one subject experienced a RT-PCR confirmed symptomatic
 425 BTI. This BTI occurred within the collection period for the t_{3m} moment and was therefore redefined
 426 as the t_{BTI} timepoint for this participant. As described in **Figure 1**, a nasopharyngeal swab was
 427 collected additionally to the blood tubes drawn via venipuncture.

428 This case concerned a woman in her thirties who presented with general malaise, dry cough and
 429 dyspnea 46 days after receiving the booster vaccine. The subject was ill for seven days but without
 430 the need for hospitalization. Based on the WHO COVID-19 severity score (38), the subject was
 431 classified as experiencing a mild SARS-CoV-2 infection. A few days prior to the BTI, this
 432 participant reported to have been in close contact with a hospitalized COVID-19 patient. A
 433 complete overview of both the humoral and cellular immune parameters at the t_{BTI} timepoint of this
 434 subject are listed in **Table 1**.

435 **Table 1. Summary of both humoral and cellular parameters of the subject with symptomatic**
 436 **BTI.**

Parameter	BTI	Range: minimum to maximum (based on values of other subjects)
Anti-S IgG (index)	36.23	2.720 – 36.53
Anti-RBD IgG (IU/mL)	1370	< 160.0 – 2446
Anti-S IgA (index)	8.814	0.719 – 8.814
Anti-N IgG (index)	0.126	0.031 – 0.666
In vitro neutralization (percentage inhibition)	96.54	22.44 – 96.67
VSV pseudovirus neutralization * (SNT50)	584	NA
Circulating RBD specific B cells (%)	0.12	0.02 – 0.25
IFN- γ release (mIU/mL)	2806.63	204.800 – 8523.00
CD69 ⁺ T _C cells ** (%)	14.40	5.240 – 40.15
CD69 ⁺ T _H cells ** (%)	11.13	6.470 – 33.88
CD69 ⁺ T _{CFH} cells ** (%)	9.88	3.56 – 45.61
CD40L ⁺ T _H cells ** (%)	0.98	0.08 – 2.61
CD40L ⁺ T _{CFH} cells ** (%)	0.022	0.000 – 1.070

healthcare workers

437 * This neutralization assay was performed with the D614G mutant strain of SARS-CoV-2. **
438 These values are taken from the condition with specific stimulation of the T cells with SARS-CoV-
439 2 peptides. Abbreviations: BTI = breakthrough infection, S = spike, N = nucleocapsid, RBD =
440 receptor-binding domain, VSV = vesicular stomatitis virus, IFN- γ = interferon- γ , NA = not
441 applicable.

442

443 In summary, at time of presenting with a symptomatic BTI, this participant displayed a functional
444 serological response (both in vitro neutralization and in pseudovirus assay) as well as SARS-CoV-
445 2 specific T-cell reactivity. Moreover, a population of circulating RBD specific B cells could be
446 observed. In order to investigate whether this BTI could be ascribed to any of the currently known
447 VoC, whole viral genome sequencing was performed on the nasopharyngeal swab. Genome
448 sequencing revealed the presence of the B.1.1.7 Pango lineage, which is also known as the alpha
449 VoC.

450 **4 Discussion**

451 In this study, we report on SARS-CoV-2 specific B and T cell immunity in healthcare workers in
452 a supraregional hospital in Belgium three months after BNT162b2 vaccination. Importantly, during
453 this study, both the number of occupied hospital and intensive care beds increased substantially
454 defining the start of the so-called third SARS-CoV-2 infection wave in Belgium (from 15 February
455 2021 onwards) (39). Besides increasing virus circulation, also the emergence of multiple VoC,
456 including alpha (B.1.1.7), beta (B.1.351) and gamma (P1) variants are known to boost infection
457 rates, in particular since vaccination coverage in the general population was still low at that time
458 (14,40).

459 Serological findings in this cohort were comparable with those described by other groups that
460 studied the serology status post booster BNT162b2 vaccination at different timepoints, i.e. ranging
461 between 2 and 12 weeks post primary vaccination (41–48). Of note, many of these studies
462 monitored vaccine induced antibody responses in patients suffering from a myriad of pathologies
463 (41–43). In addition, the net effect of vaccination is often difficult to highlight as in many studies
464 subjects with earlier natural SARS-COV-2 infection are not excluded (27,49). Three months post
465 vaccination, spike-specific IgA levels were less pronounced compared to IgG levels, the latter
466 observed in all participants of our cohort. A more rapid waning of SARS-CoV-2 IgA antibodies
467 compared to IgG was reported by Wisnewski et al (50). A significant but moderate correlation
468 between spike-specific IgG and IgA was observed, which was in line with findings by other groups
469 (50–52). However, the key question here is in fact not the net level of antigen specific vaccine-
470 induced antibodies, but whether these antibodies are truly protective and thus able to neutralize
471 docking of SARS-CoV-2 virus particles to the human ACE-2 receptor on target cells. Indeed, nAbs
472 that were able to almost completely block the RBD binding to human ACE-2 could be retrieved in
473 all but one participant, confirming the high efficacy rate of the BNT162b2 vaccine after three
474 months. In line with the findings by others (50,52,53), both anti-S and anti-RBD IgG titers were
475 identified as moderate correlates for antibody functionality. Of note, the borderline in vitro
476 neutralization observed in one subject could not be attributed to assay-specific technical issues, as
477 a similar result was observed in an in-house developed test (data not shown). With both IgG and
478 IgA anti-S antibodies just above detection limit, either the mRNA-vaccine encoded spike protein

healthcare workers

479 is less immunogenic in this subject or antibody titers – and most likely also functionality – are
480 decreasing more rapidly. In an environment with high virus circulation, including VoC, this person
481 could be more at risk to develop a BTI. Overall, our findings add to high neutralization efficacy of
482 the BNT162b2 vaccine reported by others at earlier timepoints (51,54). Of note, binding and
483 neutralization assays were performed with the Wuhan variant of SARS-CoV-2 encoded by the
484 BNT162b2 vaccine. In other words, one might show high antibody titers and functional
485 neutralization to the original virus strain that could prove to be biologically less relevant against
486 the mutated target proteins of the emergent VoC.

487 Currently, there is not yet much information available concerning the dynamics and longevity of
488 humoral immunity upon SARS-CoV-2 vaccination. Circulating antigen specific B cells are
489 considered to be a surrogate marker for the resident antigen specific B cells present within the
490 secondary lymphoid organs that are essential to establish B cell memory (18,55–57). Interestingly
491 and opposite to findings by Ciabattini et al. (18), circulating RBD specific B cells were only
492 detectable in one third of the study participants at 3 months post vaccination. In line with the latter,
493 we were only able to retrieve RBD specific B cells in a fraction of convalescent patients (Imbrechts
494 et al., submitted), again in contrast with findings by others such as the group of Nussenzweig et al
495 (48). Of the 10 individuals that displayed circulating RBD specific B cell clones, a correlation was
496 observed between the abundance of RBD-specific B cells on the one hand and both serology and
497 antibody functionality on the other hand (**Figure 4B-C**). As no signs of ongoing natural infection
498 were found, these data suggest that at least in these participants, the germinal center driven humoral
499 immunity is still being built up three months post mRNA vaccination. Shifting viewpoint from
500 vaccination to COVID-19 treatment options, our findings suggest that PBMCs from vaccinated
501 donors could serve as a source to sort out RBD specific B cell clones able to produce strong nAbs
502 of therapeutic interest. This technique has already been performed with PBMCs from convalescent
503 individuals and already led to the development of several promising nAbs (e.g. LY-CoV555 (58),
504 REGN10933 and REGN10987 (59), ABBV-2B04 (60), TY027 (61) and 3B8 (Imbrechts et al.
505 submitted)) of which some are being evaluated in phase III trials or are already approved by the
506 FDA.

507 Specific T cell responses upon BNT162b2 vaccination were already documented in the original
508 phase I/II trial by Sahin et al (24,25). In addition, other groups reported a SARS-CoV-2 specific
509 IFN- γ release in either immunocompromised patients (41,62,63), dialysis patients (45,64) or
510 healthcare workers at different timepoints up to four weeks post vaccination (7,27,28). In line with
511 these results, we could clearly observe SARS-CoV-2 specific IFN- γ release in all subjects up to
512 three months post vaccination. Moreover, we were able to include T cell phenotyping as secondary
513 read-out to the whole blood IGRA, hereby eliminating the need for PBMCs nor expensive peptide
514 pools covering the most prominent MHC haplotypes in a given population. Using this approach,
515 we were able to show SARS-CoV-2 specific activation of both T_C and T_H cell subsets which
516 implies that the SARS-CoV-2 specific antigens in this assay were presented on both MHC class I
517 and II proteins respectively. This was also shown in reports from both Braun et al. (65) and Gimenez
518 et al. (66) in which they used a related SARS-CoV-2 antigen pool to stimulate T cells and found
519 respectively an upregulation of activated CD4⁺ and CD8⁺ T cells. Besides membrane expression
520 of CD69 as general early T cell activation marker, we were able to show upregulation of CD40L
521 both in total T_H and in the CXCR5⁺ T_{CFH} subsets. Both early T cell activation and membrane
522 CD40L expression are correlated with the release of type II interferon, confirming that BNT162b2
523 vaccination induces a T_{HI} response (25). In addition, as CD40L is one of the key costimulatory

healthcare workers

524 molecules involved in both antibody class switching and BCR affinity maturation (55), CD40L
525 expression on T_H and in particular on CXCR5⁺ T_{CFH} (47) suggests that in vivo antigen re-exposure
526 will most likely lead to a massive and rapid T cell dependent antibody recall response, the latter
527 being exactly the overall goal of vaccination.

528 Next, we addressed whether the humoral and cellular immune parameters measured in this study
529 were associated to each other. From the PCA analysis, two different clusters could be identified
530 based on the loadings plot with PC 2. Interestingly, these clusters included all the parameters
531 determined within B or T cell immunity. This suggests that measuring only one or two parameters
532 from both the humoral and cellular immune response is sufficient to respectively predict 60 to 80
533 percent of the overall variability observed in this cohort (**Figure 8C**). Also, the approximate angle
534 of 90 degrees between both clusters emphasizes the absence of any correlation between each other.

535 Within the three month monitoring time window in this cohort, there was one subject who
536 developed a mild symptomatic BTI (incidence of 3.22 %) although the incidence rate reported in
537 the BNT162b2 phase III trial was very low (< 0.05 %, 8 cases out of 18,198) (67). Of note, one
538 must be careful not to overinterpret this high incidence rate due to the small size of this study. In
539 addition, healthcare workers might be more at risk than the general population, especially during a
540 new infection wave including emergent VoC. Although, it must be mentioned that a recently
541 published report of the Belgian Healthcare Knowledge Center – that included surveillance data
542 since the start of the vaccination campaign in Belgium – mentioned that the national incidence of
543 symptomatic BTI within the general population (of which 71.2% were vaccinated with
544 Comirnaty[®]) was only 0.20 % (68). Antonelli et al. stated that vaccinated people who developed a
545 BTI had mostly milder symptoms and were approximately half less likely to report symptoms of
546 Long COVID-19 Syndrome than infected unvaccinated people (69). This was also the case in our
547 subject as she had a mild infection and recovered completely after seven days. Interestingly, this
548 subject showed a clear vaccine-induced immune response including SARS-CoV-2 specific T cell
549 activity, positive titers of both anti-S and anti-RBD IgG antibodies with a high neutralization
550 efficacy (confirmed in an established pseudovirus assay) and had a small but clearly detectable
551 population of circulating RBD specific B cells. Here, the latter could very well represent the recall
552 response to natural infection in this subject. Whole genome sequencing retrieved that the subject
553 was infected with the alpha variant which was at that time the upcoming VoC within the first phase
554 of the third wave in Belgium. Antibody repertoire profiling of the subject with BTI compared to a
555 pool of age and gender matched controls could yield interesting information, in particular when
556 compared to other vaccine BTI profiles.

557 At last, it must be noted that this trial has several limitations. Firstly, the number of subjects is
558 rather limited and was based on a power analysis for the serological and IFN- γ release read-outs.
559 Hence, this design is less suited to pick up rather unexpected events such as BTI. Larger studies
560 that look at both arms of the adaptive immune response months after vaccination are needed to
561 further finetune our findings and to characterize BTI more reliable. Secondly, only SARS-CoV-2
562 naive individuals were included in this study. The pronounced recall response due to vaccination
563 in convalescent individuals has been described and even led to the discussion whether these
564 individuals should receive one rather than two vaccine doses. Addressing this was beyond our
565 scope as we specifically aimed to study the BNT162b2 vaccine-induced de novo immune response
566 in a real-world setting. Thirdly, the emergence of new and potentially more dangerous SARS-CoV-
567 2 variants leads the binding and neutralization assays available at any given time. In this

healthcare workers

568 perspective, running neutralization assays with VoC RBD could give deeper insights in the breadth
569 of the vaccine-induced functional immunity. Finally, long-term sustainability of the vaccine-
570 induced immune response can only be truly considered when looking even beyond the three month
571 timepoint. This will be particularly relevant as we are slowly progressing from a global pandemic
572 state to a genuine endemic circulation of the SARS-CoV-2 virus.

573 **5 Conclusion**

574 Three months post BNT162b2 mRNA vaccination, previously naive healthcare workers show
575 functional but individually distinct humoral and cellular immune responses to SARS-CoV-2 that
576 do not guarantee protection against the emerging VoC.

577 **6 Conflict of Interest**

578 The authors ZD and KD declare a possible conflict of interest as they are employees of the Institut
579 für Experimentelle Immunologie affiliated to EUROIMMUN Medizinische Labordiagnostika AG
580 (Lübeck, Germany). This company provided following materials for this study: EUROIMMUN
581 SARS-CoV-2 IGRA kit (no. ET 2606-3003), EUROIMMUN interferon-gamma ELISA (no. EQ
582 6841-9601), EUROIMMUN SARS-CoV-2 NeutraLISA (no. EI 2606-9601-4) and in-house
583 produced RBD-biotin.

584 **7 Author Contributions**

585 BC, NC, MI, NG and WM contributed to the conception and design of the manuscript. BC, KC,
586 AV, NC, JVC, XB, MI, NG and WM contributed to the acquisition, analysis or interpretation of
587 data. BC, KC, AV, NC, MI, ZD, KD, KV, NG, SDM and WM have drafted the work or
588 substantively revised it.

589 **8 Funding**

590 Internal KU Leuven funding

591 **9 Acknowledgments**

592 The authors would like to thank the people from BIOGNOST CV, Heule (Belgium) for their
593 support.

594 **10 References**

- 595 1. WHO. World Health Organization: Coronavirus [Internet]. 2021. Available from:
596 https://www.who.int/health-topics/coronavirus#tab=tab_1
- 597 2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DKW, et al. Detection of
598 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Eurosurveillance*. 2020 Jan
599 23;25(3):2000045.
- 600 3. Zhang Y-Z. Novel 2019 coronavirus genome - SARS-CoV-2 coronavirus - Virological
601 [Internet]. *Virological.org*. 2020. p. 1–7. Available from: [https://virological.org/t/novel-](https://virological.org/t/novel-2019-coronavirus-genome/319)
602 [2019-coronavirus-genome/319](https://virological.org/t/novel-2019-coronavirus-genome/319)

healthcare workers

- 603 4. OMS. IHR Emergency Committee on Novel Coronavirus (2019-nCoV) [Internet]. Geneva,
604 Switzerland. 2020. p. 1–4. Available from: [https://www.who.int/director-](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov))
605 [general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov))
606 [on-novel-coronavirus-\(2019-ncov\)](https://www.who.int/director-general/speeches/detail/who-director-general-s-statement-on-ihr-emergency-committee-on-novel-coronavirus-(2019-ncov))
- 607 5. Romani G, Dal Mas F, Massaro M, Cobiauchi L, Modenese M, Barcellini A, et al.
608 Population Health Strategies to Support Hospital and Intensive Care Unit Resiliency
609 during the COVID-19 Pandemic: The Italian Experience. *Popul Health Manag.* 2021 Apr
610 1;24(2):174–81.
- 611 6. FDA. Pfizer-BioNTech COVID-19 Vaccine Public Assessment Report. 2021.
- 612 7. EMA - Committee for Medicinal Products for Human Use. Pfizer-BioNTech COVID-19
613 Vaccine EMA Public Assessment Report. 2021.
- 614 8. EMA - Committee for Medicinal Products for Human Use. Moderna COVID-19 Vaccine
615 EMA Public Assessment Report. 2021.
- 616 9. FDA. Moderna COVID-19 Vaccine Public Assessment Report. 2021.
- 617 10. EMA - Committee for Medicinal Products for Human Use. AstraZeneca EMA Public
618 Assessment Report. Vol. 31. 2021.
- 619 11. EMA - Committee for Medicinal Products for Human. COVID-19 Vaccine Janssen EMA
620 Public Assessment Report. Vol. 31. 2021.
- 621 12. FDA. Janssen COVID-19 Vaccine Public Assessment Report. 2021.
- 622 13. Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of
623 Age and Older - Full Text View - ClinicalTrials.gov [Internet]. 2021. Available from:
624 [https://clinicaltrials.gov/ct2/show/NCT04904549?term=sanofi+gsk&cond=SARS-CoV-](https://clinicaltrials.gov/ct2/show/NCT04904549?term=sanofi+gsk&cond=SARS-CoV-2&draw=2&rank=1)
625 [2&draw=2&rank=1](https://clinicaltrials.gov/ct2/show/NCT04904549?term=sanofi+gsk&cond=SARS-CoV-2&draw=2&rank=1)
- 626 14. WHO. Tracking SARS-CoV-2 Variants [Internet]. WHO. 2021. p. 1–13. Available from:
627 <https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/>
- 628 15. Otto SP, Day T, Arino J, Colijn C, Dushoff J, Li M, et al. The origins and potential future
629 of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic. *Curr Biol.* 2021
630 Jul 26;31(14):R918–29.
- 631 16. Kim Y, Gaudreault NN, Meekins DA, Perera KD, Bold D, Trujillo JD, et al. Effects of
632 Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-
633 Mediated Virus Entry and Neutralization. *bioRxiv Prepr Serv Biol* [Internet]. 2021 Aug
634 25; Available from: <https://pubmed.ncbi.nlm.nih.gov/34462749/>
- 635 17. Bettini E, Locci M. SARS-CoV-2 mRNA Vaccines: Immunological mechanism and
636 beyond. *Vaccines.* 2021 Feb 1;9(2):1–20.
- 637 18. Ciabattini A, Pastore G, Fiorino F, Polvere J, Lucchesi S, Pettini E, et al. Evidence of
638 SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the

healthcare workers

- 639 BNT162b2 mRNA Vaccine. *Front Immunol.* 2021 Sep 28;12:3751.
- 640 19. Forgacs D, Jang H, Abreu RB, Hanley HB, Gattiker JL, Jefferson AM, et al. SARS-CoV-2
641 mRNA Vaccines Elicit Different Responses in Immunologically Naïve and Pre-Immune
642 Humans. *Front Immunol.* 2021 Sep 27;12:4000.
- 643 20. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, et al.
644 Duration of antiviral immunity after smallpox vaccination. *Nat Med.* 2003 Sep
645 1;9(9):1131–7.
- 646 21. Kedzierska K, Koutsakos M. The ABC of major histocompatibility complexes and T cell
647 receptors in health and disease. *Viral Immunol.* 2020 Apr 1;33(3):160–78.
- 648 22. Gil-Manso S, Carbonell D, López-Fernández L, Miguens I, Alonso R, Buño I, et al.
649 Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2
650 After the Administration of Covid-19 mRNA Vaccines Requires Several Days. *Front*
651 *Immunol.* 2021 Oct 4;12:3970.
- 652 23. Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D, et al. Mini Review
653 Immunological Consequences of Immunization With COVID-19 mRNA Vaccines:
654 Preliminary Results. Vol. 12, *Frontiers in Immunology*. Frontiers Media S.A.; 2021. p.
655 677.
- 656 24. Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Phase I/II
657 study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature.* 2020 Aug
658 12;586(7830):589–93.
- 659 25. Sahin U, Muik A, Derhovanessian E, Vogler I, Kranz LM, Vormehr M, et al. COVID-19
660 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. *Nature.* 2020 Sep
661 30;586(7830):594–9.
- 662 26. Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, et al. BNT162b
663 vaccines protect rhesus macaques from SARS-CoV-2. *Nature.* 2021 Apr 8;592(7853):283–
664 9.
- 665 27. Casado JL, Haemmerle J, Vizcarra P, Rodriguez-Dominguez M, Velasco T, Velasco H, et
666 al. T-cell response after first dose of BNT162b2 SARS-CoV-2 vaccine among healthcare
667 workers with previous infection or cross-reactive immunity. *Clin Transl Immunol.*
668 2021;10(9).
- 669 28. Painter MM, Mathew D, Goel RR, Apostolidis SA, Pattekar A, Kuthuru O, et al. Rapid
670 induction of antigen-specific CD4+ T cells is associated with coordinated humoral and
671 cellular immunity to SARS-CoV-2 mRNA vaccination. *Immunity.* 2021 Sep
672 14;54(9):2133-2142.e3.
- 673 29. Glatman-Freedman A, Bromberg M, Dichtiar R, Hershkovitz Y, Keinan-Boker L. The
674 BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of
675 breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis
676 using individualised data. *EBioMedicine.* 2021 Oct 1;72.

healthcare workers

- 677 30. Blanquart F, Abad C, Ambroise J, Bernard M, Cosentino G, Giannoli JM, et al.
678 Characterisation of vaccine breakthrough infections of sars-cov-2 delta and alpha variants
679 and within-host viral load dynamics in the community, france, june to july 2021.
680 Eurosurveillance. 2021 Sep 16;26(37).
- 681 31. Tene Y, Levytskyi K, Adler A, Halutz O, Paran Y, Goldshmidt H, et al. An outbreak of
682 SARS-CoV-2 infections among hospital personnel with high mRNA vaccine uptake. Infect
683 Control Hosp Epidemiol. 2021
- 684 32. Bahl A, Johnson S, Maine G, Garcia MH, Nimmagadda S, Qu L, et al. Vaccination
685 reduces need for emergency care in breakthrough COVID-19 infections: A multicenter
686 cohort study. Lancet Reg Heal - Am. 2021 Sep;100065.
- 687 33. EMA. Committee for Medicinal Products for Human Use. Guideline on bioanalytical
688 method validation. EMEA/CHMP/EWP/192217/2009 Rev 1 Corr 2** [Internet]. 2012;1–
689 23. Available from: www.ema.europa.eu/contact
- 690 34. NIBSC NI for BS and Controls. WHO International Standard First WHO International
691 Standard for anti-SARS-CoV-2 immunoglobulin (human) NIBSC code: 20/136
692 Instructions for use (Version 2.0, Dated 17/12/2020) [Internet]. 2020. Available from:
693 http://www.nibsc.org/standardisation/international_standards.aspx
- 694 35. Sanchez-Felipe L, Vercruyse T, Sharma S, Ma J, Lemmens V, Van Looveren D, et al. A
695 single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate. Nature.
696 2021 Feb 11;590(7845):320–5.
- 697 36. Van Cleemput J, van Snippenberg W, Lambrechts L, Dendooven A, D’Onofrio V, Couck
698 L, et al. Organ-specific genome diversity of replication-competent SARS-CoV-2. Nat
699 Commun. 2021 Nov 16;12(1):1–11.
- 700 37. Zar JH. Biostatistical Analysis. 5th ed. 2010.
- 701 38. Diaz, Janet; Appiah, John; Askie, Lisa; Baller, April; Banerjee, Anshu; Barkley, Shannon;
702 Bertagnolio, Silvia; Hemmingsen, Bianca; Bonet, Mercedes; Cunningham J. COVID-19 :
703 Clinical management Living guidance [Internet]. World Health Organization. 2021. p. 81.
704 Available from: [https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-](https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1)
705 1
- 706 39. Sciensano. Covid-19 Surveillance Frequently Asked Questions [Internet]. 2021. Available
707 from: [https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-](https://covid-19.sciensano.be/sites/default/files/Covid19/COVID-19_FAQ_ENG_final.pdf)
708 19_FAQ_ENG_final.pdf
- 709 40. Baele G, Cuypers L, Maes P, Dellicour S, Keyaerts E, Wollants E, et al. Genomic
710 surveillance of SARS-CoV-2 in Belgium [Internet]. Vol. 2021. 2021. Available from:
711 [https://www.uzleuven.be/nl/laboratoriumgeneeskunde/genomic-surveillance-sars-cov-2-](https://www.uzleuven.be/nl/laboratoriumgeneeskunde/genomic-surveillance-sars-cov-2-belgium)
712 belgium
- 713 41. Amodio D, Ruggiero A, Sgrulletti M, Pighi C, Cotugno N, Medri C, et al. Humoral and
714 Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19
715 Vaccine in Patients Affected by Primary Immunodeficiencies. Front Immunol. 2021 Oct

healthcare workers

- 716 4;12:3947.
- 717 42. Braun-Moscovici Y, Kaplan M, Braun M, Markovits D, Giryas S, Toledano K, et al.
718 Disease activity and humoral response in patients with inflammatory rheumatic diseases
719 after two doses of the Pfizer mRNA vaccine against SARS-CoV-2. *Ann Rheum Dis*. 2021
720 Oct 1;80(10):1317–21.
- 721 43. Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, et al. Humoral
722 immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated
723 with high-efficacy disease-modifying therapies. *Ther Adv Neurol Disord*. 2021;14.
- 724 44. Grupper A, Sharon N, Finn T, Cohen R, Israel M, Agbaria A, et al. Humoral response to
725 the pfizer bnt162b2 vaccine in patients undergoing maintenance hemodialysis. *Clin J Am
726 Soc Nephrol*. 2021 Jul 1;16(7):1037–42.
- 727 45. Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H, et al. The
728 Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in
729 Hemodialysis Patients. *Front Immunol*. 2021 Jun 16;12:2390.
- 730 46. Lustig Y, Sapir E, Regev-Yochay G, Cohen C, Fluss R, Olmer L, et al. BNT162b2
731 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a
732 prospective, single-centre, longitudinal cohort study in health-care workers. *Lancet Respir
733 Med*. 2021 Sep 1;9(9):999–1009.
- 734 47. Segundo DS, Comins-Boo A, Irure-Ventura J, Renuncio-García M, Roa-Bautista A,
735 González-López E, et al. Immune assessment of BNT162b2 m-RNA-spike based vaccine
736 response in adults. *Biomedicines*. 2021 Aug 1;9(8).
- 737 48. Wang Z, Schmidt F, Weisblum Y, Muecksch F, Barnes CO, Finkin S, et al. mRNA
738 vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature*. 2021 Apr
739 22;592(7855):616–22.
- 740 49. Hirotsu Y, Amemiya K, Sugiura H, Shinohara M, Takatori M, Mochizuki H, et al. Robust
741 Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the
742 First Dose in Previously Infected Individuals and After the Second Dose in Uninfected
743 Individuals. *Front Immunol*. 2021 Aug 26;12:3457.
- 744 50. Wisniewski A V., Luna JC, Redlich CA. Human IgG and IgA responses to COVID-19
745 mRNA vaccines. *PLoS One*. 2021 Jun 1;16(6 June):e0249499.
- 746 51. Pratesi F, Caruso T, Testa D, Tarpanelli T, Gentili A, Gioè D, et al. Bnt162b2 mrna sars-
747 cov-2 vaccine elicits high avidity and neutralizing antibodies in healthcare workers.
748 *Vaccines*. 2021 Jun 1;9(6).
- 749 52. Salvagno GL, Henry BM, Di Piazza G, Pighi L, De Nitto S, Bragantini D, et al. Anti-spike
750 s1 iga, anti-spike trimeric igg, and anti-spike rbd igg response after bnt162b2 covid-19
751 mrna vaccination in healthcare workers. *J Med Biochem*. 2021;40(4):327–34.
- 752 53. Naaber P, Tserel L, Kangro K, Sepp E, Jürjenson V, Adamson A, et al. Dynamics of
753 antibody response to BNT162b2 vaccine after six months: a longitudinal prospective

healthcare workers

- 754 study. *Lancet Reg Heal - Eur.* 2021 Sep;100208.
- 755 54. Favresse J, Gillot C, Di Chiaro L, Eucher C, Elsen M, Van Eeckhoudt S, et al. Neutralizing
756 antibodies in covid-19 patients and vaccine recipients after two doses of bnt162b2.
757 *Viruses.* 2021 Jul 1;13(7).
- 758 55. Byazrova M, Yusubalieva G, Spiridonova A, Efimov G, Mazurov D, Baranov K, et al.
759 Pattern of circulating SARS-CoV-2-specific antibody-secreting and memory B-cell
760 generation in patients with acute COVID-19. *Clin Transl Immunol.* 2021 Jan
761 1;10(2):e1245
- 762 56. Turner JS, O'Halloran JA, Kalaidina E, Kim W, Schmitz AJ, Zhou JQ, et al. SARS-CoV-2
763 mRNA vaccines induce persistent human germinal centre responses. *Nature.* 2021 Jun
764 28;596(7870):109–13.
- 765 57. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to
766 SARS-CoV-2 assessed for up to 8 months after infection. *Science.* 2021 Feb 5;371(6529).
- 767 58. An EUA for Bamlanivimab - A Monoclonal Antibody for COVID-19. Vol. 325, *JAMA -*
768 *Journal of the American Medical Association.* *JAMA*; 2021. p. 880–1.
- 769 59. An EUA for Casirivimab and Imdevimab for COVID-19 | The Medical Letter, Inc.
770 [Internet]. 2021. Available from: <https://secure.medicalletter.org/w1614a>
- 771 60. Alsoussi WB, Turner JS, Case JB, Zhao H, Schmitz AJ, Zhou JQ, et al. A Potently
772 Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection. *J Immunol.* 2020
773 Aug 15;205(4):915–22.
- 774 61. NCT04649515. Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans.
775 <https://clinicaltrials.gov/show/NCT04649515> [Internet]. 2020; Available from:
776 <https://clinicaltrials.gov/ct2/show/NCT04649515>
- 777 62. Moyon Q, Sterlin D, Miyara M, Anna F, Mathian A, Lhote R, et al. BNT162b2 vaccine-
778 induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus
779 erythematosus. *Ann Rheum Dis.* 2021 Oct 4;annrheumdis-2021-221097.
- 780 63. Lasagna A, Agustoni F, Percivalle E, Borgetto S, Paulet A, Comolli G, et al. A snapshot of
781 the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2
782 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.
783 *ESMO Open.* 2021 Oct;6(5):100272.
- 784 64. Van Praet J, Reynders M, De Bacquer D, Viaene L, Schoutteten M, Caluwé R, et al.
785 Predictors and Dynamics of the Humoral and Cellular Immune Response to SARS-CoV-2
786 mRNA Vaccines in Hemodialysis Patients: A Multicenter Observational Study. *J Am Soc*
787 *Nephrol.* 2021 Sep 29;ASN.2021070908.
- 788 65. Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F, et al. SARS-CoV-2-reactive
789 T cells in healthy donors and patients with COVID-19. *Nature.* 2020 Jul
790 29;587(7833):270–4.

healthcare workers

- 791 66. Giménez E, Albert E, Torres I, Remigia MJ, Alcaraz MJ, Galindo MJ, et al. SARS-CoV-2-
792 reactive interferon- γ -producing CD8+ T cells in patients hospitalized with coronavirus
793 disease 2019. *J Med Virol.* 2021 Jan 1;93(1):375–82. /
- 794 67. European Medicines Agency. Comirnaty | European Medicines Agency [Internet]. Ema.
795 2021. Available from: <https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty>
- 796 68. Jespers V, Leroy R, Hulstaert F, Wyndham Thomas C, Van Montfort T, Van Damme
797 UAntwerpen P, et al. Rapid Review of the Evidence on a COVID-19 Booster Dose After a
798 Primary Vaccination Scheule Report for the Task Force Vaccination (Version With
799 Summary in Dutch). 2021.
- 800 69. Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and
801 disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID
802 Symptom Study app: a prospective, community-based, nested, case-control study. *Lancet*
803 *Infect Dis.* 2021 Sep
- 804